Abstract
Ticagrelor is an orally active, reversibly bind of the P2Y12 receptor that can prevent ADP-mediated platelet activation and has a faster onset of action than clopidogrel. A stability-indicating HPLC method for the determination of ticagrelor in coated tablets was developed and validated. Chromatographic analysis was performed in a Shimadzu liquid chromatograph, equipped with Phemomenex® C18 column (250 x 4.6 mm, 5 μm), using a mobile phase composed of acetonitrile: water with 0.5% triethylamine (57:43 v/v) pH 7.0, at 0.7 ml/min flow rate and injection volume of 20 μl. Under the conditions established, the method demonstrated to be specific, without interference from formulation excipients, stability- indicating, linear (r = 0.9990) in the concentration range of 45.0 to 105.0 μg/ml, precise (RSD=0.71), accurate (99.61% of mean recovery) and robust. It can be successfully applied to ticagrelor tablets quality control, being adequate for routine analysis.
Keywords: Antiplatelet, HPLC, quality control, stability-indicating assay, tablets, ticagrelor.
Current Pharmaceutical Analysis
Title:Determination of the New Antiplatelet Agent Ticagrelor in Tablets by Stability-Indicating HPLC Method
Volume: 10 Issue: 4
Author(s): Caren Gobetti, Rubia Lazzaretti Pereira, Andreas Sebastian Loureiro Mendez and Cássia Virginia Garcia
Affiliation:
Keywords: Antiplatelet, HPLC, quality control, stability-indicating assay, tablets, ticagrelor.
Abstract: Ticagrelor is an orally active, reversibly bind of the P2Y12 receptor that can prevent ADP-mediated platelet activation and has a faster onset of action than clopidogrel. A stability-indicating HPLC method for the determination of ticagrelor in coated tablets was developed and validated. Chromatographic analysis was performed in a Shimadzu liquid chromatograph, equipped with Phemomenex® C18 column (250 x 4.6 mm, 5 μm), using a mobile phase composed of acetonitrile: water with 0.5% triethylamine (57:43 v/v) pH 7.0, at 0.7 ml/min flow rate and injection volume of 20 μl. Under the conditions established, the method demonstrated to be specific, without interference from formulation excipients, stability- indicating, linear (r = 0.9990) in the concentration range of 45.0 to 105.0 μg/ml, precise (RSD=0.71), accurate (99.61% of mean recovery) and robust. It can be successfully applied to ticagrelor tablets quality control, being adequate for routine analysis.
Export Options
About this article
Cite this article as:
Gobetti Caren, Pereira Lazzaretti Rubia, Mendez Sebastian Loureiro Andreas and Garcia Virginia Cássia, Determination of the New Antiplatelet Agent Ticagrelor in Tablets by Stability-Indicating HPLC Method, Current Pharmaceutical Analysis 2014; 10 (4) . https://dx.doi.org/10.2174/1573412910666140610211656
DOI https://dx.doi.org/10.2174/1573412910666140610211656 |
Print ISSN 1573-4129 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-676X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of the Gut Microbiota in Energy Metabolism and Metabolic Disease
Current Pharmaceutical Design How Should We Treat Hypertension and Dyslipidemia in Patients with Prediabetes?
Current Pharmaceutical Design Lifestyle Factors and Endothelial Function
Current Vascular Pharmacology Reducing Gabaergic Inhibition Restores Cognitive Functions in a Mouse Model of Down Syndrome
CNS & Neurological Disorders - Drug Targets Nitric Oxide Donors as Potential Drugs for the Treatment of Vascular Diseases Due to Endothelium Dysfunction
Current Pharmaceutical Design Roles of Arterial Baroreceptor Reflex During Bezold-Jarisch Reflex
Current Cardiology Reviews Effectiveness and Safety of Digoxin on Chronic Heart Failure
Current Pharmaceutical Analysis Elevated Inflammatory Parameter Levels Negatively Impact Populations of Circulating Stem Cells (CD133+), Early Endothelial Progenitor Cells (CD133+/VEGFR2+), and Fibroblast Growth Factor in Stroke Patients
Current Neurovascular Research Imaging Neuroinflammation in Ischemic Stroke and in the Atherosclerotic Vascular Disease
Current Vascular Pharmacology Clinical Features and Disease Damage Risk Factors in an Egyptian SLE Cohort: A Multicenter Study
Current Rheumatology Reviews Repurposing Pharmaceuticals as Neuroprotective Agents for Cerebral Malaria
Current Clinical Pharmacology The Emerging Role of Vascular Endothelial Growth Factor (VEGF) in Vascular Homeostasis: Lessons from Recent Trials with Anti-VEGF Drugs
Current Vascular Pharmacology A High Burden of Ischemic Stroke in Regions of Eastern/Central Europe is Largely Due to Modifiable Risk Factors
Current Neurovascular Research The Pathophysiology of Heart Failure in Children: The Basics
Current Cardiology Reviews Pro Atrial Natriuretic Peptide (1-30) and 6-keto PGF<sub>1α</sub> Activity Affects Na<sup>+</sup> Homeostasis in Non-modulating Hypertension
Current Hypertension Reviews The “Sympathetic” Kidney: Multiples Effects of Renal Sympathetic Nerve Ablation
Current Hypertension Reviews Elevated Levels of Soluble Fibrin in Patients with Thrombosis or a Pre- Thrombotic State
Vascular Disease Prevention (Discontinued) Interest of α2-Adrenergic Agonists and Antagonists in Clinical Practice: Background, Facts and Perspectives
Current Topics in Medicinal Chemistry How Would Composite Traditional Chinese Medicine Protect the Brain – An Example of the Composite Formula “Pien Tze Huang”
Current Medicinal Chemistry No Significant Effect of 7,8-Dihydroxyflavone on APP Processing and Alzheimer-Associated Phenotypes
Current Alzheimer Research